Stocktoria
ARTELO BIOSCIENCES, INC. ARTL
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2015-10-13
ARTELO BIOSCIENCES, INC. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $5.4M | $6.0M | $5.7M | $4.3M | $3.8M | $2.8M | $1.9M | $1.1M | $1.2M | — |
| Operating income | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$9.4M | -$7.4M | -$4.7M | -$3.2M | -$2.3M | -$232,789 |
| Interest expense | $194,000 | $0 | $0 | $5,000 | — | $0 | — | — | — | $2,100 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M | -$9.4M | -$7.4M | -$4.7M | -$2.2M | -$2.3M | -$234,889 |
| EPS (diluted) | $-12.52 | $-18.30 | $-3.14 | — | — | — | — | $-1.46 | $-1.84 | — |
| Operating cash flow | -$8.5M | -$8.3M | -$8.2M | -$8.0M | — | -$6.1M | -$4.3M | -$2.8M | -$1.6M | -$216,821 |
| Cash & equivalents | $600,000 | — | — | $6.9M | $12.2M | $6.6M | $2.1M | $4.4M | $337,424 | $572,775 |
| Total assets | $2.8M | $4.7M | $13.0M | $20.4M | $28.3M | $12.6M | $4.4M | $6.5M | $396,998 | $574,275 |
| Total liabilities | $4.1M | $1.8M | $1.3M | $1.0M | $1.1M | $593,000 | $501,000 | — | — | — |
| Shareholders' equity | -$1.3M | $2.9M | $11.8M | $19.4M | $27.2M | $12.0M | $3.9M | $5.5M | -$134,974 | $544,837 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.